Stay updated with the latest subcutaneous-tissue news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on subcutaneous-tissue topics.
VMPL Mumbai (Maharashtra) [India], March 31: Rusan Healthcare Pvt. Ltd., the marketing and distribution arm of Rusan Pharma Limited, an integrated global pharmaceutical company, has announced the launch of the multi-dose delivery pen device - APOSAN® 3ml Pen (Apomorphine Hydrochloride solution for injection in cartridge)(10mg/ml)(3ml pre-filled cartridges) for treatment of motor fluctuations commonly known as 'ON-OFF' episodes in patients suffering from Parkinson's disease (PD). In 2018, Rusan ...Read More >
Mumbai (Maharashtra) [India], March 31: Rusan Healthcare Pvt. Ltd., the marketing and distribution arm of Rusan Pharma Limited, an integrated global pharmaceutical company, has announced the launch of the multi-dose delivery pen device - APOSAN® 3ml Pen (Apomorphine Hydrochloride solution for injection in cartridge)(10mg/ml)(3ml pre-filled cartridges) for treatment of motor fluctuations commonly known as 'ON-OFF' episodes in patients suffering from Parkinson's disease (PD). Also Read | Ashok Kh ...Read More >
New Delhi, Jul 16 (PTI) Biocon Biologics on Wednesday said it has received approval from the US health regulator to market a diabetes treatment medication. The company, a unit of Biocon Ltd, has received approval from the US Food and Drug Administration (USFDA) for Kirsty as the first and only interchangeable biosimilar to NovoLog (Insulin Aspart). Kirsty is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. The m ...Read More >
FDA Approves Kirsty (insulin aspart-xjhz), an Interchangeable Biosimilar to NovoLog BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India: July 15, 2025 -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (FDA) has approved Kirsty™ (Insulin Aspart-xjhz), 100 units/mL as the first and only interchangeable* biosimilar to NovoLog® (Insulin ...Read More >
READ MORE: Ozempic-maker's new fat-busting drug cuts body weight by a quarter - and it comes as a jab or a PILL The Ozempic boom has seen a drug widely used to treat diabetes and manage obesity in adults transform into 'miracle' weight loss jab that's coveted by anyone with a few extra kilos to shed. Ozempic and other alternatives like Mounjaro and Wegovy are all different brand names for the drug semaglutide that mimics the the actions of GLP-1 - a hormone in the brain that regulates appetite ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.